COMPANY PROFILE / #1599
GEn1E Lifesciences
Palo Alto, CAVenture Capital-Backed
OVERVIEW
Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. The company offers a proprietary drug development model that integrates mechanistic endotyping, kinase modulation, and data-driven clinical insights, enabling researchers and clinicians to accelerate discovery-to-clinic timelines, optimize treatment efficacy, and advance novel therapies for complex diseases.
已融资25.55
最新估值135.52
员工数6
成立年份2018
公司概况
- Companies
- GEn1E Lifesciences
- Description
- Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. The company offers a proprietary drug development model that integrates mechanistic endotyping, kinase modulation, and data-driven clinical insights, enabling researchers and clinicians to accelerate discovery-to-clinic timelines, optimize treatment efficacy, and advance novel therapies for complex diseases.
- Website
- www.gen1e.com
- HQ Location
- Palo Alto, CA
- Year Founded
- 2018
- Keywords
- biotechnology research, clinical stage pharmaceutical, immunological disease therapy, immunomodulatory drugs, inflammatory disease, machine learning platform, novel therapeutics, precision medicine, solid tumor drug
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 25.55
- First Financing Date
- 31-Mar-2020
- First Financing Size
- 3.00
- First Financing Valuation
- 42.86
- Last Financing Date
- 23-Dec-2025
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 5.52
- Last Financing Valuation
- 135.52
- Last Financing Status
- Completed
- Last Known Valuation
- 135.52
- Last Known Valuation Date
- 23-Dec-2025
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 201.27
- Valuation Estimate Growth Rate
- 48.52%
- Active Investors
- 10X Capital, Advagen Holdings, Allen Chang, BoxOne Ventures, Cenk Serdar, Clear Ventures, DealBench, Endurance28, Farzad Nazem, Francois Nader, Gaingels, George Bickerstaff, Harmonix Fund, Inflect Capital, Jeffery Brown, Joe Fedacsek, John Jersin, John Parent, John-Paul Gallo, Jonathan Feldstein, Khosla Ventures, Matthew Cheng, Milad Alucozai, Mohan Kanchi, Nitin Agarwal, Peter Haider, Rahul Shendure, Rob Mark, Saad AlSogair, Sid Hartman, Siddharth Bajpai, StartX (US), Thomas Ebeling, UM Ventures, Vertex Albian Capital, Vision Capital Ventures, Vituity, Y Combinator
- # Active Investors
- 38
- Acquirers
- —
团队与联系人
- Employees
- 6
- Employee Growth %
- 0.00%
- Employee History
- 2025: 6, 2024: 6, 2023: 6, 2022: 6, 2021: 4, 2020: 2, 2019: 2, 2018: 2
- Primary Contact
- Soujanya Bhumkar
- Primary Contact Title
- Co-Founder, Executive of AI/ML Platform & Board Member
- Primary Contact Email
- soujanya@gen1elifesci.com
- Primary Contact Phone
- +1 (650) 799-7121
增长与经营
- Revenue
- 1.80
- Revenue Growth %
- —
- Growth Rate
- 10.00%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 100
- Size Multiple
- 8.08x
- Size Multiple % Change
- 1.45%
- Size Multiple Change
- 0.12x
- Size Multiple Percentile
- 90
- Majestic Referring Domains
- 210
- SimilarWeb Unique Visitors
- 177
- SimilarWeb Unique Visitors Change
- 8
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 6%
- Success Probability Over Time – 3 Year
- 18%
- Success Probability Over Time – 5 Year
- 30%
记录来源：public.companies · 原始序号 #1599 · 所有字段均按数据库原值展示。